Chinanews client, Beijing, August 13 (Reporter Xie Yiguan) This year's new crown pneumonia epidemic has brought many pharmaceutical companies to the front under the banner of "epidemic prevention", becoming the leaders in the economic semi-annual report, and has the performance of pharmaceutical companies It even soared dozens of times and stood out from the crowd of listed companies.
Make money from the epidemic!
Pharmaceutical companies make semi-annual reports of "Excellent Students"
"One mask is hard to find" and "one instrument doubles". During the severe epidemic, the prices of masks, infrared meters, and ventilators have been rising, helping medical device companies to increase their performance.
Data map: Volunteers enter the mask company to help produce. Photo courtesy of Zhejiang Communist Youth League Committee
Among them, it must be mentioned that Intech Medical, which produces protective products such as gloves, is expected to achieve a net profit of 1.9 billion to 2.1 billion yuan attributable to shareholders of listed companies in the first half of the year, a year-on-year increase of 2581.8%-2864.1%.
The non-woven fabric manufacturer Xinlong Holdings also has the same increase in performance. It is expected to achieve a net profit of 140 million to 190 million yuan attributable to shareholders of listed companies in the first half of the year, an increase of 2232.85%-2994.58% over the same period last year.
Mask manufacturers are also "big winners." For example, Yangpu Medical expects the net profit attributable to shareholders of listed companies in the first half of the year to be 113 million yuan to 118 million yuan, a year-on-year increase of 590%-620%.
Mindray Medical's performance in the first half of the year was also good. It is expected to achieve a net profit attributable to shareholders of listed companies from 3.269 billion yuan to 3.506 billion yuan, an increase of 38% to 48% over the same period last year.
The continuous spread of the global epidemic has led to a surge in testing demand, and has also allowed companies that produce testing reagents to make a lot of money. In the first half of the year, Oriental Bio and Daan Gene's net profits attributable to shareholders of listed companies were 524 million yuan and 762 million yuan, an increase of 1477.45% and 1159.13% year-on-year.
"Some testing, equipment, and some API companies benefit from factors such as the epidemic, and their semi-annual performance is expected to achieve relatively high growth." Tianfeng Securities analyst Zheng Wei said that as of August 2, there were 128 companies in the pharmaceutical and biological sector. The performance forecast was released. Among them, 30 companies are expected to increase their net profit by more than 100%, and 33 companies are expected to increase their net profit by 0-100%.
Bullish!
The pharmaceutical sector was born ten times bulls
Compared with impressive performance, pharmaceutical companies have a more dazzling performance in the capital market.
In the first half of the first half of the "drinking and taking medicine" market, the flush ifind data shows that as of August 11, the biomedical index (399441) has increased by 108.63% since the beginning of the year.
Data map: Workers of CSPC are packing anti-epidemic drugs such as Arbidol hydrochloride tablets. Photo by China News Agency reporter Zhai Yujia
Individual stocks in the pharmaceutical sector are even more shining. Among the top ten bull stocks in the first half of the year, Intech Medical, Shushi Bio, Weiming Pharmaceutical, Aoxiang Pharmaceutical, and Zhende Medical took the top five positions.
Among them, Yingke Medical, which has the largest increase, has a cumulative increase of 671.73% in the first half of the year, and Shuoshi Bio, which has a cumulative increase of 383.5%, is far behind.
"Performance and stock price fly together", after the announcement of the results on the evening of July 10, Intech Medical received the daily limit. As of August 11, Ingram Medical’s share price has risen by 909.73% during the year, and its market value has increased by 33.5 billion yuan. It once rose by more than 1,000% before becoming the first non-technological innovation board ten times the A-share stock this year.
In addition, Shuoshi Biology, Zhende Medical, Daan Gene, and Zhifei Biology increased by 448.87%, 436.51%, 341.23%, and 217.76% respectively during the year.
"Betting on these stocks, Giant last year, Porsche this year." Some netizens said.
Soaring wealth!
A number of pharmaceutical giants were selected into the rich list
The soaring stock price has also allowed the big names of pharmaceutical companies to rapidly increase their wealth.
The "Special Report on Global Entrepreneurs Wealth Changes Four Months After the Epidemic" released by the Hurun Research Institute shows that in the four months ending May 31, 2020, the wealth of Hengrui Medicine, Sun Piaoyang and Zhong Huijuan of Hexion Medicine has increased US$4 billion; Mindray Medical’s Xu Hang wealth increased by 31%.
On June 14, 2019, Huijuan Zhong, Chairman and CEO of Hansen Pharmaceuticals, celebrated its successful listing. Photo by China News Agency reporter Zhang Wei
Recently, Forbes China released the TOP50 list of the richest in medical and health care. Zhong Huijuan, chairman of the board of Hansen Pharmaceuticals, topped the list with a net worth of US$19.8 billion. From January 23 to July 17, the company’s Hong Kong stock price rose 38%. Zhong Huijuan's husband and Sun Piaoyang, chairman of Hengrui Pharmaceutical Group, ranked third with a net worth of $16.8 billion.
Li Xiting and Xu Hang, ranked second and fourth, are the co-founders of Mindray Medical. From January 23 to July 17, Mindray Medical’s share price surged 82%, and the net worth of Li Xiting and Xu Hang increased to $17.5 billion and $16.3 billion, respectively.
In addition, Yiling Pharmaceutical founder Wu Yiling and Yuyue founder Wu Guangming are also included in the 2020 Forbes Global Billionaires list with a net worth of US$1.5 billion and US$2 billion respectively.
The stock price has risen sharply, and some bigwigs are busy cashing out. For example, on July 23, Zhifei Biological issued a shareholding reduction announcement stating that Wu Guanjiang, a shareholder holding more than 5% of the shares, and people acting in concert, planned to conduct centralized bidding transactions within 6 months after 15 trading days from April 3. The reduction of holdings was not more than 29.6 million shares. As of July 22, 16 million shares had been reduced, and about 1.564 billion yuan was cashed out.
There is uncertainty
Can the performance myth continue?
In the announcement, Oriental Biotech stated that there are uncertainties in the global prevention and control of the new crown pneumonia epidemic, overseas market industry policies, and national export policies. Coupled with intensified competition in the new crown testing product market, there is a certain degree of whether sales will continue to maintain substantial growth in the future Uncertainty.
From the “difficult to find a cover” at the beginning of the year to now readily available, Zhende Medical and Xinlong Holdings also have this concern. Both companies said in the announcement that they are facing uncertainty about performance growth.
Ventilators and monitors with higher technical barriers are in better condition. Mindray Medical stated in a survey of reception institutions that the epidemic has rapidly enlarged the market capacity of hospital ventilators, and it is imperative for many countries to increase the strategic reserve of hospital ventilators. The company believes that the hospital ventilators market will continue to grow in the future. .
"Although the pharmaceutical index is currently at a high point and many stocks are at high historical valuations, pharmaceutical stocks are still a scarce resource in the uncertain global epidemic situation." Bohai Securities believes that the performance of multiple stocks Exceeding expectations, the market outlook for pharmaceutical stocks has greater expectations.
"In the long run, the demand for medicine is huge and expanding. The complexity and arduousness of medicine requires companies to make long-term and huge investment, but it also forms a huge barrier." New Era Securities analyst Shen Rui said, coupled with pharmaceutical stocks With strong resistance to external risks, strong growth, and the possibility of a long-term epidemic, the growth of profits will gradually digest the high valuation of stocks. (Finish)